Pharmacologic treatment of depression in patients with heart disease

Psychosomatic Medicine

Volumn 67, Issue SUPPL. 1, 2005, Pages

  Roose, Steven P ^a,b   Miyazaki, Marissa ^b  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Antidepressants; Heart rate variability; Ischemic heart disease; Selective serotonin reuptake inhibitors; Tricyclics

Indexed keywords

AMFEBUTAMONE; ANTIARRHYTHMIC AGENT; ECAINIDE; FLECAINIDE; FLUOXETINE; MORACIZINE; NORTRIPTYLINE; PAROXETINE; PEMOLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; HEART DISEASE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE VARIABILITY; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE; SUDDEN DEATH; THROMBOCYTE AGGREGATION INHIBITION;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CARDIOVASCULAR DISEASES; DEPRESSION; HEART RATE; HUMANS; MYOCARDIAL ISCHEMIA; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 19244387489     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.psy.0000163455.43226.bf     Document Type: Review

References (27)

1. Roose SP, Glassman AH. Cardiovascular effects of TCAs in depressed patients with and without heart disease. J Clin Psychiatry Monogr 1989;7:1-19.
2. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of ecainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
3. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33.
4. Selzer A, Wray HW. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;10:17-26.
5. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989;111:107-11.
6. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990;82:1106-16.
7. Bigger JT Jr. Implications of the cardiac arrhythmia suppression trial for antiarrhythmic drug treatment. Am J Cardiol 1990;65:3D-10D.
8. Greenberg HM, Dwyer EM Jr, Hochman JS, Steinberg JS, Echt DS, Peters RW. Interaction of ischemia and ecainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST 1. Br Heart J 1995;74:631-5.
9. Glassman AH, Roose SP, Bigger JT Jr. The safety of TCAs in cardiac patients: risk/benefit reconsidered. JAMA 1993;269:2673-5.
10. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. AM J Cardiol 1987;59:256-62.
11. Bonnemeier H, Hartmann F, Uwe KH, Bode F, Katus HA, Richard G. Course and prognostic implications of QT interval and QT interval variability after primary coronary angioplasty in acute myocardial infarction. J Am Coll Cardiol 2001;37:44-50.
12. Roose SP, Dalack GW, Woodring S. Death, depression, and heart disease. J Clin Psychiatry Supp 1991;52:34-9.
13. Yeragani VK, Pohl R, Balon R, Ramesh C, Glitz D, Jung I, Sherwood P. Heart rate variability in patients with major depression. Psychiatry Res 1991;37:35-46.
14. Yeragani VK. Major depression and long-term heart period variability. Depress Anxiety 2000;12:51-2.
15. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I. A comparison of paroxetine to nortriptyline in depressed patients with IHD. JAMA 1997;279:287-91.
16. Yeragani VK, Pohl R, Jampala VC, Balon R, Ramesh C, Srinivasan K. Increased QT variability in patients with panic disorder and depression. Psychiatry Res 2000;93:225-35.
17. Barbey JT, Roose SP. SSRI safety in overdose. J. Clin Psychiatry 1998;59(suppl 15):42-8.
18. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease. Arch Gen Psychiatry 1998;55:580-592.
19. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with IHD after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000;20:137-40.
20. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, Finkel MS, Krishnan KR, Gaffney M, Harrison W, Califf RM, O'Connor CM, Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003 108:939-44.
21. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894-8.
22. Roose SP, Classman AH, Attia E, Woodring S. Giardina EGV, Bigger J Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998;155:5:660-5.
23. Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, Kuijpers PM, Wellens HJ, Van Praag HM. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000;62:783-9.
24. Pohl R, Balon R, Jayaraman A, Doll RG, Yeragani V. Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans. J Psychosom Res 2003;55:247-51.
25. Shapiro PA, Lesperance F, Frasure-Smith N, O'Connor CM, Baker B, Jiang JW, Dorian P, Harrison W, Glassman AH. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Am Heart J 1999;137:1100-6.
26. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-9.
27. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EGV. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991;148:512-6.